7,455 Shares in Guardant Health, Inc. $GH Bought by Ieq Capital LLC

Ieq Capital LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 7,455 shares of the company’s stock, valued at approximately $1,118,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GH. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at about $35,000. Parallel Advisors LLC boosted its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the period. Ascentis Independent Advisors acquired a new position in shares of Guardant Health during the first quarter worth about $38,000. Hollencrest Capital Management bought a new position in shares of Guardant Health during the first quarter worth about $41,000. Finally, EFG International AG bought a new position in shares of Guardant Health during the fourth quarter worth about $41,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the transaction, the chief executive officer owned 1,881,336 shares of the company’s stock, valued at $285,097,657.44. The trade was a 7.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 548,318 shares of company stock valued at $82,501,873 in the last three months. Corporate insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Mizuho boosted their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Morgan Stanley raised their price target on shares of Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Stephens lifted their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Sanford C. Bernstein boosted their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 2nd. Finally, BTIG Research increased their target price on shares of Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Trading Up 3.6%

Shares of GH opened at $170.92 on Thursday. The company’s fifty day simple moving average is $156.17 and its 200 day simple moving average is $120.00. Guardant Health, Inc. has a 1-year low of $53.40 and a 1-year high of $176.58. The company has a market cap of $22.94 billion, a price-to-earnings ratio of -48.97 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. The business’s revenue was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.44) EPS. As a group, research analysts forecast that Guardant Health, Inc. will post -2.98 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.